-
公开(公告)号：KR1020080049562A
公开(公告)日：2008-06-04
申请号：KR1020060120227
申请日：2006-11-30
Applicant: 가톨릭대학교 산학협력단
Inventor： 전신수
CPC classification number: A61K35/28 , A61K35/51 , A61K9/0019
Abstract: A mesenchymal stem cell isolated from human umbilical cord blood is provided to be differentiated into a neuron or a neuroglia cell with moving to an injured portion when engrafted in vivo, thereby being usefully used for cell replacement therapy and gene therapy of treating nerve injury diseases. An internal administering therapeutic agent for treating nerve injury diseases comprises a mesenchymal cell as an effective ingredient, wherein the mesenchymal cell is a mesenchymal stem cell derived from umbilical cord blood and the never injury disease is selected from the group consisting of stroke, Parkinson's disease, Alzheimer's disease, Pick's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic central nervous system disease and spinal cord injury disease. A method for treating the nerve injury disease comprises a step of administering a therapeutically effective amount of the therapeutic agent internally.
Abstract translation: 提供从人脐带血分离的间充质干细胞，在体内移植到移植到损伤部分时分化为神经元或神经胶质细胞，从而有用地用于治疗神经损伤疾病的细胞替代疗法和基因治疗。 用于治疗神经损伤疾病的内用药治疗剂包括间充质细胞作为有效成分，其中所述间充质细胞是源自脐带血的间充质干细胞，永不伤害疾病选自中风，帕金森氏病， 阿尔茨海默病，皮克病，亨廷顿舞蹈病，肌萎缩性侧索硬化，创伤性中枢神经系统疾病和脊髓损伤疾病。 用于治疗神经损伤疾病的方法包括在内部施用治疗有效量的治疗剂的步骤。
-
公开(公告)号：KR1020070058255A
公开(公告)日：2007-06-08
申请号：KR1020050117261
申请日：2005-12-03
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K38/2013 , A61K38/2086
Abstract: A composition comprising activated marrow stromal cells(MSCs) is provided to show strong cytotoxicity against glioma cell line, thereby being used as a source of an effective adoptive cell transmission in adults and kids suffering from malignant glioma. The composition for treating malignant glioma comprises MSC as an effective ingredient. The MSC is activated by interleukin-2(IL-2), a combination of IL-2 and IL-15, granulocyte monocyte colony stimulating factor(GM-CSF), a combination of GM-CSF and IL-2, wherein the MSC expresses perforin, gamma-INF, FasL more than before it is activated.
Abstract translation: 提供包含活化的骨髓基质细胞（MSC）的组合物以显示对胶质瘤细胞系的强细胞毒性，从而被用作成年人和恶性胶质瘤患儿的有效的继代细胞传播的来源。 用于治疗恶性胶质瘤的组合物包括MSC作为有效成分。 MSC由IL-2和IL-15的组合，粒细胞单核细胞集落刺激因子（GM-CSF），GM-CSF和IL-2的组合被IL-2（IL-2）激活，其中MSC 表达穿孔素，γ-INF，FasL比活化前更多。
-
-
Patent Agency Ranking
公开(公告)号：KR101832489B1
公开(公告)日：2018-02-26
申请号：KR1020110036097
申请日：2011-04-19
Applicant: 가톨릭대학교 산학협력단
Abstract: 본발명자들은줄기세포에서베타-카테닌(beta-catenin)이인산화됨으로서신경세포로의분화가유도된다는사실을확인하고, 줄기세포의신경세포로의분화촉진용물질의스크리닝방법인본 발명을완성하였다. 따라서본 발명의베타-카테닌을타겟으로, 줄기세포에서의후보물질의베타-카테닌인산화활성여부를측정하여줄기세포의신경세포로의분화촉진용물질의스크리닝방법을제공한다. 따라서본 발명은줄기세포가신경세포로서분화할수 있는신호전달을가능하게하는물질을신속하고효율적으로검출해낼 수있게하며, 더나아가다양한신경질환의새로운치료법으로평가받는세포치료제의발전을앞당길수 있다는효과가있다.
Abstract translation: 本发明的发明人证实，通过干细胞中的β-连环蛋白的氧化诱导向神经元的分化，并且完成了本发明作为用于促进干细胞向神经元分化的物质的筛选方法 。 因此，本发明提供了通过测量干细胞中靶向β-连环蛋白的候选物质的β-连环蛋白磷酸化活性来筛选促进干细胞分化为神经元的物质的方法。 因此，本发明能够迅速且有效地检测能够将干细胞分化为神经细胞的信号传导物质，并且进一步促进被评价为用于各种神经疾病的新的治疗方法的细胞治疗剂的开发 这是有效的。
-
公开(公告)号：KR1020160001126A
公开(公告)日：2016-01-06
申请号：KR1020140078978
申请日：2014-06-26
Applicant: 가톨릭대학교 산학협력단
Abstract: 본발명은 IL-8이처리된줄기세포의현저한혈관신생기능에관한것으로, 보다구체적으로는 IL-8이처리된중간엽줄기세포가 AKt 및 ERK를인산화시키는기작을통해 VEGF의분비를촉진시키고, 혈관신생을유도하여뇌졸중등의허혈성질환을효과적으로치료할수 있는용도에관한것이다.
Abstract translation: 本发明涉及IL-8治疗的干细胞的显着的血管生成功能，更具体地，涉及通过诱导血管生成有效治疗缺血性疾病如中风等的用途。 IL-8处理的间充质干细胞通过用于磷酸化AKt和ERK的机制促进VEGF的分泌。
-
公开(公告)号：KR1020150012136A
公开(公告)日：2015-02-03
申请号：KR1020130087594
申请日：2013-07-24
Applicant: 가톨릭대학교 산학협력단
IPC: A61K35/28 , A61K35/44 , A61K31/404 , A61P35/00
CPC classification number: A61K35/28 , A61K31/405 , A61K33/00 , A61K2300/00
Abstract: The present invention relates to an anticancer use of combination of stem cells secreting TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand) and MK886, and more specifically, to a function of reinforcing trail-intermediated cell killing activity by sensitizing neuroglioma cells by molecular mechanism such as CHOP inducement, upregulation of DR5 expression, downregulation of surviving, activation of caspase, activation of p38 MAPK, etc according to combination thereof.
Abstract translation: 本发明涉及分泌TRAIL（肿瘤坏死因子相关凋亡诱导配体）和MK886的干细胞的组合的抗癌用途，更具体地涉及通过分子对神经胶质瘤细胞的敏感性来增强跟踪中间细胞杀伤活性的功能 机制如CHOP诱导，DR5表达的上调，存活的下调，胱天蛋白酶的活化，p38MAPK的活化等。
-
公开(公告)号：KR101467631B1
公开(公告)日：2014-12-05
申请号：KR1020120054470
申请日：2012-05-22
Applicant: 가톨릭대학교 산학협력단
Abstract: 본발명은 HSV-TK(herpes simplex virus type I thymidine kinase) 등의자살유전자를발현하는줄기세포에발프로산(valproic acid, VPA)을조합하여사용하는자살유전자항암치료법에관한것으로, 신경교종세포와, 상기발프로산처리된자살유전자발현-줄기세포를공동배양시킴으로써간극결합(gap junction)을상향조절하고방관자효과(bystander effect)를강화시킴으로써항암효과를상승시키는기능에관한것이다.
-
公开(公告)号：KR1020100132878A
公开(公告)日：2010-12-20
申请号：KR1020090051688
申请日：2009-06-10
Applicant: (주)차바이오텍 , 가톨릭대학교 산학협력단
IPC: A61K9/06 , A61P41/00 , A61K31/728 , A61K31/336
CPC classification number: A61K31/728 , A61K9/06
Abstract: PURPOSE: An anti-adhesion agent containing hyaluronic acid epoxide derivative hydrogel and a method for manufacturing the same are provided to prevent adhesion between tissues without side effects. CONSTITUTION: An anti-adhesion agent contains hyaluronic acid epoxide derivative hydrogen. The particle size of the hydrogel is 100-300 um. The viscosity and crosslinking density of the hydrogel are 100,000 cP (0.02 Hz)-6,000,000 cP (0.02 Hz) and 0.2 mol%-100 mol%, respectively. The hydrogel is prepared by reacting hyaluronic acid and epoxide crosslinking agent in NaOH solution or crossliking 0.1-200 weight parts of crosslinking agent based on 100 weight parts of repeat unit of the hyaluronic acid.
Abstract translation: 目的：提供含有透明质酸环氧化物衍生物水凝胶的防粘连剂及其制造方法，以防止组织之间的粘连而无副作用。 构成：抗粘连剂含有透明质酸环氧化物衍生物氢。 水凝胶的粒径为100-300微米。 水凝胶的粘度和交联密度分别为100,000cP（0.02Hz）-6,000,000cP（0.02Hz）和0.2mol％-100mol％。 水凝胶是通过使透明质酸和环氧化物交联剂在NaOH溶液中反应制备的，或者以100重量份的透明质酸重复单元交联0.1-200重量份交联剂。
-
-
-
-
-
-
-
Search Results
28
records
(took 0.03 seconds)
